[
    [
        {
            "time": "2021-06-04",
            "original_text": "贝达药业：埃克替尼术后辅助治疗适应症获得药品注册证书 将对公司营收带来积极影响",
            "features": {
                "keywords": [
                    "贝达药业",
                    "埃克替尼",
                    "术后辅助治疗",
                    "药品注册证书",
                    "营收"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业：埃克替尼术后辅助治疗适应症获得药品注册证书 将对公司营收带来积极影响",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-06-04",
            "original_text": "贝达药业：盐酸埃克替尼片获得药品注册证书",
            "features": {
                "keywords": [
                    "贝达药业",
                    "盐酸埃克替尼片",
                    "药品注册证书"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业：盐酸埃克替尼片获得药品注册证书",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-06-04",
            "original_text": "贝达药业：盐酸埃克替尼片（商品名：凯美纳?）术后辅助治疗适应症获药品注册证",
            "features": {
                "keywords": [
                    "贝达药业",
                    "盐酸埃克替尼片",
                    "凯美纳",
                    "术后辅助治疗",
                    "药品注册证"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业：盐酸埃克替尼片（商品名：凯美纳?）术后辅助治疗适应症获药品注册证",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-06-04",
            "original_text": "重磅！贝达药业埃克替尼术后辅助治疗获批上市",
            "features": {
                "keywords": [
                    "贝达药业",
                    "埃克替尼",
                    "术后辅助治疗",
                    "获批上市"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "重磅！贝达药业埃克替尼术后辅助治疗获批上市",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 10,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-06-04",
            "original_text": "午间公告2021年6月4日星期五",
            "features": {
                "keywords": [],
                "sentiment_score": 0.0,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "午间公告2021年6月4日星期五",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 2,
                "Impact": 2,
                "Duration": 2,
                "Entity_Density": 1,
                "Market_Scope": 1,
                "Time_Proximity": 6,
                "Headline_Structure": 3,
                "Source_Recency": 5
            }
        },
        {
            "time": "2021-06-04",
            "original_text": "贝达药业(300558.SZ)：埃克替尼术后辅助治疗适应症获批",
            "features": {
                "keywords": [
                    "贝达药业",
                    "埃克替尼",
                    "术后辅助治疗",
                    "适应症",
                    "获批"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业(300558.SZ)：埃克替尼术后辅助治疗适应症获批",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-06-04",
            "original_text": "2021年医药生物行业半年度策略报告：乘风破浪会有时 辅助生殖新机遇",
            "features": {
                "keywords": [
                    "医药生物",
                    "行业策略",
                    "辅助生殖",
                    "新机遇"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "2021年医药生物行业半年度策略报告：乘风破浪会有时 辅助生殖新机遇",
                "Correlation": 4,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 4,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        }
    ]
]